Aarti Pharmalabs reported Q4 FY26 standalone revenue of ₹580 crore (+9% YoY), but EBITDA fell to ₹134 crore (-5% YoY) and PAT dropped to ₹62 crore (-30% YoY), impacted by a ₹33...
✓ Verified against BSE filing
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Geopolitical tensions have caused significant increases in raw material and logistics costs, impacting margins, especially in the API segment where cost pass-through is difficult.
high · management_commentaryManagement noted that existing orders in the API segment cannot be repriced, and future price increases depend on competitive dynamics.
medium · analyst_questionCDMO revenue is lumpy due to project-based deliveries, and large customer orders require significant inventory financing without advances.
medium · analyst_questionA ₹33 crore forex loss in FY26 (including on foreign currency loans) highlights exposure to currency fluctuations, with potential for further hits.
medium · data_observation